Glycine to tryptophan substitution in type I collagen in a patient with OI type III: a unique collagen mutation. by Nuytinck, Lieve et al.
doi: 10.1136/jmg.37.5.371
 2000 37: 371-375J Med Genet
 
Lieve Nuytinck, Turgut Tükel, Hülya Kayserili, et al.
 
collagen mutation
collagen in a patient with OI type III: a unique 
Glycine to tryptophan substitution in type I
 http://jmg.bmj.com/content/37/5/371.full.html
Updated information and services can be found at: 
These include:
References
 http://jmg.bmj.com/content/37/5/371.full.html#related-urls
Article cited in: 
 
 http://jmg.bmj.com/content/37/5/371.full.html#ref-list-1
This article cites 15 articles, 10 of which can be accessed free at:
service
Email alerting
the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in the box at
Topic collections
 (6409 articles)Calcium and bone   
 (7236 articles)Connective tissue disease   
 
Articles on similar topics can be found in the following collections
Notes
 http://jmg.bmj.com/cgi/reprintform
To order reprints of this article go to: 
 http://jmg.bmj.com/subscriptions
 go to: Journal of Medical GeneticsTo subscribe to 
 group.bmj.com on March 31, 2010 - Published by jmg.bmj.comDownloaded from 
Glycine to tryptophan substitution in type I
collagen in a patient with OI type III: a unique
collagen mutation
Lieve Nuytinck, Turgut Tükel, Hülya Kayserili, Memnune Yüksel Apak, Anne De Paepe
Abstract
We report a unique glycine substitution in
type I collagen and highlight the clinical
and biochemical consequences. The
proband is a 9 year old Turkish boy with
severely deforming osteogenesis imper-
fecta (OI). Biochemical analysis of (pro)
collagen type I from a skin fibroblast
culture showed both normal and over-
modified á chains. Molecular analysis
showed a G>T transversion in the
COL1A2 gene, resulting in the substitution
of glycine by tryptophan at position 277 of
the á2(I) collagen chain. Glycine substitu-
tions in type I collagen are the most
frequent cause of the severe and lethal
forms of OI. The phenotypic severity
varies according to the nature and locali-
sation of the mutation. Substitutions of
glycine by tryptophan, which is the most
voluminous amino acid, have not yet been
identified in type I collagen or any other
fibrillar collagen. The severe, though non-
lethal OI phenotype associated with this
mutationmay appear surprising in view of
the huge size of the tryptophan residue.
The fact that the mutation resides within a
so called “non-lethal” region of the á2(I)
collagen chain supports a regional model
in phenotypic severity for á2(I) collagen
mutations, in which the phenotype is
determined primarily by the nature of the
collagen domain rather than the type of
glycine substitution involved.
(J Med Genet 2000;37:371–375)
Keywords: osteogenesis imperfecta; COL1A2; tryp-
tophan; collagen
Osteogenesis imperfecta (OI) is a heritable
connective tissue disorder characterised by a
varying degree of bone fragility. Generally, four
major clinical and genetic subtypes are recog-
nised (table 1).1
OI is caused by mutations in one of the two
á chains of type I collagen, the principal com-
ponent of the extracellular matrix in bone and
skin. Type I collagen is a fibrillar collagen com-
posed of two á1(I) chains, encoded by the
COL1A1 gene, and one á2(I) chain, encoded
by the COL1A2 gene. In the majority of
patients with mild OI a decreased amount of
structurally normal type I collagen is found
whereas in the more severe OI phenotypes (OI
types II, III, and IV) a structurally abnormal
type I collagen protein is seen. Most com-
monly, a structural defect is caused by the sub-
stitution of a glycine residue in the helical part
of one or both type I collagen á chains. In the
vast majority of cases, the mutations are
“private” in that they have only been reported
in one single person/family.
Glycine substitutions are by far the most fre-
quently found amino acid alteration not only in
type I collagen but also in the other collagen
types known to form fibrils. Fibrillar collagens
have an uninterrupted triple helical domain
constructed from repeating Gly-X-Y triplets.
The presence of glycine, the amino acid with
the smallest side chain, in every third position
of a collagen á chain is a prerequisite for
correct folding of the three á chains into a col-
lagen triple helix.
Here we present the clinical and biochemical
consequences of a glycine to tryptophan
substitution in the procollagen á2(I) chain in a
patient with OI type III. Tryptophan, an amino
acid residue which is not usually present in the
type I collagen triple helical region, consists of
an aromatic side chain composed of an indol
ring bound by a methylene group. The result is
a huge, neutral amino acid with a non-polar
side chain, as such being very hydrophobic.
The mutation presented here is unique in that
it is the first reported tryptophan for glycine
substitution in type I collagen causing OI.
Materials and methods
CLINICAL SUMMARY
The proband is a 9 year old Turkish boy, the
only child of a non-consanguineous couple.
The father and mother were 33 and 28 years
old respectively at the time of his birth. They
Table 1 The clinical features and mode of inheritance for all types of osteogenesis
imperfecta are presented according to the classification of Sillence et al1
OI type Clinical features Inheritance
OI type I (mild) Normal or near normal stature
with little or no deformity
AD
Variable number of fractures
Distinctly blue sclerae throughout
life
Hearing loss in about 50% of cases
OI type II (lethal) Lethal in perinatal period or in
utero
AD (new mutations)
Severe dwarfism with marked
bowing and deformities of the
extremities
AR (rare)
Extreme bone fragility
OI type III (severely deforming) Progressively deforming bones AD
Very short stature AR (uncommon)
Dentinogenesis imperfecta
common
OI type IV (moderately severe) Variable short stature AD
Mild to moderate bone deformity
Variable fracture rate
Scoliosis/lordosis in some patients
Dentinogenesis imperfecta
common
AD: autosomal dominant; AR: autosomal recessive.
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are healthy and have no history of fractures. At
birth, the proband weighed 2300 g and had
several fractures. His length was not recorded.
Thereafter, he suVered countless other frac-
tures, mainly of the extremities and also of the
ribs. He was never able to walk or sit alone. At
the age of 6 years 3 months, he was severely
dwarfed with a length of 72 cm (below the 3rd
centile) (fig 1A) and a head circumference of
49.5 cm. He had blue sclerae, pectus carina-
tum, severely deformed limbs, and dentinogen-
esis imperfecta. Now, at the age of 9 years, his
fracture rate is still high, his limb deformities
have progressed, and his general condition has
worsened. His height is at present 83 cm
(below the 3rd centile). X rays show, besides
generalised osteoporosis, a large skull with
irregular and undermineralised calvarium and
wormian bones (fig 1B), thin ribs with old
fractures, a severely deformed pelvis, and thin
and markedly deformed long bones in the
upper and lower extremities with popcorn
deformities in the metaphyseal regions of the
long bones (fig 1C). The clinical and radiologi-
cal features correspond to the severely progres-
sive type of OI (Sillence type III).
BIOCHEMICAL COLLAGEN STUDIES
A skin biopsy was obtained from the proband
and a fibroblast culture was established under
standard conditions. After labelling with 14C-
proline, the procollagen and collagen proteins
were isolated from the medium and cell layer
and examined by SDS electrophoresis as
described by Nuytinck et al.2 Thermal stability
measurement was performed as described by
Figure 1 (A) The proband at the age of 6 years, showing severe dwarfism and deformities of the upper and lower
extremities, indicative of the severely deforming type of OI (Sillence type III). (B) X ray of the skull at the age of 9 years
showing thin, undermineralised calvarium and wormian bones. (C) X rays of the lower extremities taken at the age of 9
years, showing severe osteoporosis, thinning and bowing of the long bones, and the characteristic “popcorn” deformities in
the metaphyseal regions of the femora and tibiae.
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Bruckner and Prockop.3 The collagen process-
ing and secretion were studied by pulsed chase
experiments adapted from Forlino et al.4 Con-
fluent cells were labelled with 14C-proline for
30 minutes. Radiolabelled medium was re-
moved and replaced with serum-free BME
supplemented with ascorbic acid and 10
mmol/l cold proline. Cells were chased for 1
hour, 1.5 hours, 2 hours, 3.5 hours, 5 hours,
and 10.5 hours. At the indicated times, the
medium and cell layer were harvested sepa-
rately and supplemented with protein inhibi-
tors. The samples were run reduced without
pepsin digestion on SDS-PAGE.
MOLECULAR COLLAGEN STUDIES
Genomic DNA of the parents was isolated
from peripheral blood leucocytes using the
Qiagen-Blood miniprep kit (Qiagen Inc, Chat-
worth, CA). Genomic DNA from the proband
was isolated from dermal fibroblasts using the
Easy-DNA kit (Invitrogen). Total RNA was
isolated from cultured fibroblasts and cDNA
was obtained, using M-MLV reverse tran-
scriptase (Life Technologies) according to the
manufacturer’s instructions. PCR was per-
formed using primers for the complete
COL1A1 and COL1A2 coding regions and the
amplimers were analysed by conformation
sensitive gel electrophoresis (CSGE).5 Frag-
ments showing an aberrant migration pattern
were cloned and sequenced. The RT-PCR
findings were confirmed by genomic DNA
sequencing.
Results
BIOCHEMICAL COLLAGEN STUDIES
Polyacrylamide gel electrophoresis (PAGE-
SDS) of procollagen and pepsin digested colla-
gens from the medium and from the cell layer
showed a population of normal and of more
slowly migrating (pro)á1(I) and (pro)á2(I)
collagen chains (fig 2). The collagen type I
melting profiles showed a slight decrease of
1°C to 2°C in denaturing temperature between
the mutant and normal type I collagen chains
(data not shown). Pulse chase experiments
showed only a mild delay in processing and
secretion in comparison to a normal control
cell line (data not shown).
MOLECULAR COLLAGEN STUDIES
Molecular screening by CSGE showed one
migration shift in the COL1A2 gene fragment
covering exon 19 to exon 24 in the proband’s
cDNA. Cloning and sequencing of the relevant
COL1A2 fragment on cDNA as well as on
genomic DNA resulted in the identification of
a G to T transversion in position 1238 of the
COL1A2 cDNA sequence (EMBL accession
number Z74616), which changes the codon for
glycine (GGG) to that for tryptophan (TGG)
(fig 3) in position 277 of the proá2(I) collagen
chain. Restriction digestion with the enzyme
ApaI of the respective amplimers confirmed
the presence of the mutation in cDNA and
genomic DNA in the proband and the absence
of the mutation in genomic DNA from both
parents.
Discussion
The substitution of a glycine residue by a
bulkier amino acid in type I collagen is a com-
mon mechanism in OI. Of the 20 naturally
occurring amino acids, mutations in a codon
for glycine (GGT, GGC, GGA, GGG) can
result in the substitution by only a limited
number of amino acids. Base changes in the
first position can give rise to arginine, cysteine,
serine, tryptophan, or a stop codon. Any base
change occurring in the second position results
in the substitution of the glycine residue by
alanine, aspartic acid, glutamic acid, or valine.
All of these amino acid substitutions have been
found in both type I collagen genes, except two,
namely glycine to tryptophan and glycine to a
stop codon.
The preferential occurrence of a certain
amino acid residue as a result of a base change
in the codon for glycine is in part determined
by the relative codon usage of the glycine
codon (table 2). The tryptophan codon (TGG)
can only arise from the codon GGG, which is
the codon with the lowest prevalence in either
Figure 2 Analysis by SDS-PAGE of pepsin derived
collagens secreted in the medium (left panel) and collagens
retained in the cell layer (right panel) by cultured
fibroblasts from the proband compared to control samples.
Lanes 1, 3, 4, and 6: control samples; lanes 2 and 5: the
proband with OI type III. Broadening of the bands
(arrows) representing the á1(I) and á2(I) collagen chains
is visible in the medium as well as in the cell layer. This is
because of the presence of two diVerent populations of type I
collagen á chains, a normal and a mutant, more slowly
migrating population. In the medium as well as in the cell
layer, both populations are seen in equal proportions.
a 1(III)3
1 2 3 4 5 6
a 1(I)
a 2(I)
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the COL1A1 or COL1A2 gene. This may be
one reason why a glycine by tryptophan substi-
tution has not been reported previously in OI.6
Similarly, glutamic acid residues (GAG), which
also arise from the codon GGG, have only been
reported once in the COL1A1 gene (Nuytinck
and De Paepe, personal communication) and
once in the COL1A2 gene.7 Until now, only the
substitution of GGA by TGA resulting in a
stop codon has not been found in type I colla-
gen genes. Although nonsense mutations in the
COL1A1 gene are common in OI type I, they
arise in all cases from the substitution of
arginine for a stop codon (AGA or CGA to
TGA) in the á1(I) collagen helix.
The á2(I)-G277W substitution reported
here is localised in a microdomain of the type
I collagen molecule in which some glycine
substitutions have been characterised (fig 4).
All of the á1(I) collagen mutations described
in this region result in lethal phenotypes while
in the á2(I) chain they result in non-lethal
phenotypes. From these data, in addition to
the á2(I)-G277W substitution reported here,
one can conclude that the region in the á2(I)
collagen chain in which the mutation occurs
rather than the type of the substituting amino
acid is predominant in determining the clinical
outcome. As this is the first report of a glycine
to tryptophan substitution in type I collagen,
one can speculate that a similar substitution
either in the á1(I) or in other regions along the
á2(I) chain would result in a lethal OI pheno-
type.
On biochemical analysis, one can easily
observe the presence of normal and á1(I)
chains, a more slowly migrating population of
á1(I) chains, and also á2(I) chains in the
medium, which means that they are apparently
well secreted. There is no significant accumu-
lation of mutant á chains in the cell layer.
Thermal stability measurements showed a mild
decrease in denaturing temperature between
the mutant and normal type I collagen trimers.
These findings illustrate that a change in ther-
mal stability does not necessarily influence the
clinical outcome as already suggested earlier.8
Pulse chase experiments showed only a slight
delay in processing and secretion of the type I
collagen molecules, a phenomenon which is
often observed in OI patients with a glycine
substitution in type I collagen. As such, the in
vitro eVect of the glycine by tryptophan substi-
tution on the molecular secretion and thermal
stability is quite mild, taking into account that
tryptophan is such a huge amino acid residue.
One explanation for these findings is the
N-terminal localisation of the tryptophan resi-
due in the á2(I) collagen chain. As helix folding
of type I collagen molecules proceeds from the
C- to the N-terminal propeptide, only the
winding of the helical region N-terminal to the
substitution will be impaired.
Since each type I collagen molecule consists
of two á1(I) chains and one á2(I) chain, which
is the one mutated in this patient, half of the
type I collagen molecules produced by this
patient are expected to be normal while the
other half will be structurally defective. Since
no evidence was found in vitro for accumula-
tion of mutant type I collagen molecules in the
cell layer, one can assume that both normal
and mutant molecules are present in equal
proportions in the extracellular matrix and
available for participation in collagen fibril
formation.
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